Adipose tissue-derived mesenchymal stem cell (AT-MSC) secretome — a cell-free bioactive fraction containing exosomes, VEGF, IGF-1, HGF, cytokines, and extracellular vesicles — demonstrably accelerates telogen-to-anagen phase transition in preclinical models, increases follicle density, enhances perifollicular vascularization, and expands dermal papilla cell populations primarily through Wnt/β-catenin pathway activation. Preliminary clinical data indicate improvements in hair density and shaft thickness, particularly when secretome is combined with microneedling to enhance dermal penetration.
What makes this approach mechanistically compelling is the shift away from whole-cell transplantation toward a paracrine, cell-free strategy — sidestepping immunogenicity concerns while retaining most of the regenerative signaling. VEGF and HGF involvement also links follicular regeneration to broader vascular remodeling, suggesting synergy with scalp microcirculation. This positions AT-MSC secretome as conceptually superior to existing treatments like minoxidil or finasteride, which address symptoms rather than follicular biology.
However, this is a systematic review of heterogeneous experimental and early-phase clinical studies — not a randomized controlled trial — so causal claims remain premature. Critical gaps persist: secretome composition varies substantially across production protocols, dosing is unstandardized, and most human data lack adequate controls or long-term follow-up. Regulatory-grade manufacturing is absent. The finding is directionally exciting and mechanistically grounded, but clinically incremental until powered RCTs establish efficacy and safety benchmarks. Adults experiencing hair loss should regard this as an emerging pipeline therapy, not an actionable near-term option.